Abstract：
OBJECTIVE: To systematically review how audiometric data change over time in patients with Menière\'s disease (MD) undergoing non-ablative medical therapy.
UNASSIGNED: Medline (via PubMed), Scopus, Web of Science, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Google Scholar.
METHODS: A systematic review and meta-analysis of the literature was performed. Adult patients undergoing non-ablative medical therapy and reported duration of disease or follow-up were included and pooled estimates of pure-tone average (PTA) were tabulated. Studies were excluded if they did not use established MD, did not have pure-tone average (PTA) audiometric data, underwent ear surgery or ablative therapies, and were systematic reviews or case reports.
RESULTS: Out of 198 articles meeting full eligibility, 13 studies, involving 950 patients with MD, were included in the review and further analyzed. No effect on progression of PTA from initial diagnosis was seen between the different medical therapies within 2 years of non-ablative medical treatment. There was a significant worsening of PTA after 2 year, regardless of treatment used. High levels of heterogeneity among studies were noted up to 6 months from diagnosis ( I2 = 79%), likely reflecting differences in patient characteristics, treatment regimens, and study design. Overall, the risk of bias was low for the majority of included studies.
CONCLUSIONS: Patients diagnosed with MD who are undergoing non-ablative medical therapy should be counseled on the likelihood of worsening of hearing loss over the course of the disease despite elected treatment.
UNASSIGNED: Medline (via PubMed), Scopus, Web of Science, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Google Scholar.
METHODS: A systematic review and meta-analysis of the literature was performed. Adult patients undergoing non-ablative medical therapy and reported duration of disease or follow-up were included and pooled estimates of pure-tone average (PTA) were tabulated. Studies were excluded if they did not use established MD, did not have pure-tone average (PTA) audiometric data, underwent ear surgery or ablative therapies, and were systematic reviews or case reports.
RESULTS: Out of 198 articles meeting full eligibility, 13 studies, involving 950 patients with MD, were included in the review and further analyzed. No effect on progression of PTA from initial diagnosis was seen between the different medical therapies within 2 years of non-ablative medical treatment. There was a significant worsening of PTA after 2 year, regardless of treatment used. High levels of heterogeneity among studies were noted up to 6 months from diagnosis ( I2 = 79%), likely reflecting differences in patient characteristics, treatment regimens, and study design. Overall, the risk of bias was low for the majority of included studies.
CONCLUSIONS: Patients diagnosed with MD who are undergoing non-ablative medical therapy should be counseled on the likelihood of worsening of hearing loss over the course of the disease despite elected treatment.
摘要：
目的：系统评价接受非消融性药物治疗的梅尼埃病（MD）患者听力测量数据如何随时间变化。
■Medline（通过PubMed），Scopus,WebofScience,护理和相关健康文献累积指数(CINAHL)，谷歌学者。
方法：对文献进行系统评价和荟萃分析。纳入接受非消融性药物治疗和报告的疾病持续时间或随访的成年患者，并列出纯音平均（PTA）的汇总估计值。如果研究不使用已确定的MD，则将其排除在外，没有纯音平均(PTA)听力数据，接受了耳部手术或消融治疗，以及系统评价或病例报告。
结果：在符合完全资格的198篇文章中，13项研究，涉及950名MD患者，被纳入审查并进一步分析。在非消融性药物治疗的2年内，在不同的药物治疗之间，从初始诊断开始对PTA的进展没有影响。2年后PTA明显恶化，无论使用何种治疗。在诊断后的6个月内，研究中发现了高水平的异质性（I2=79％），可能反映了患者特征的差异，治疗方案,和研究设计。总的来说,大部分纳入研究的偏倚风险较低.
结论：诊断为MD且正在接受非消融性药物治疗的患者，尽管选择了治疗方案，但在疾病过程中听力损失恶化的可能性应被告知。
■Medline（通过PubMed），Scopus,WebofScience,护理和相关健康文献累积指数(CINAHL)，谷歌学者。
方法：对文献进行系统评价和荟萃分析。纳入接受非消融性药物治疗和报告的疾病持续时间或随访的成年患者，并列出纯音平均（PTA）的汇总估计值。如果研究不使用已确定的MD，则将其排除在外，没有纯音平均(PTA)听力数据，接受了耳部手术或消融治疗，以及系统评价或病例报告。
结果：在符合完全资格的198篇文章中，13项研究，涉及950名MD患者，被纳入审查并进一步分析。在非消融性药物治疗的2年内，在不同的药物治疗之间，从初始诊断开始对PTA的进展没有影响。2年后PTA明显恶化，无论使用何种治疗。在诊断后的6个月内，研究中发现了高水平的异质性（I2=79％），可能反映了患者特征的差异，治疗方案,和研究设计。总的来说,大部分纳入研究的偏倚风险较低.
结论：诊断为MD且正在接受非消融性药物治疗的患者，尽管选择了治疗方案，但在疾病过程中听力损失恶化的可能性应被告知。
